Other Information .
−Removed: During the three months ended September 30, 2024 , Louise Rodino-Klapac entered into and adopted a written plan for the sale of our securities that is intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information (a “Rule 10b5-1 trading plan”).
−Removed: Rodino-Klapac’s 10b5-1 trading plan has an adoption date of August 9, 2024 and an end date of November 15, 2025 , covering 28,875 options to purchase shares of common stock with a strike price of $76.36 and 24,988 shares of common stock.
+Added: During the three months ended March 31, 2025, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information.
The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q.
6 unchanged sentences
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Sarepta Therapeutics, Inc.
+Added: Amended and Restated Bylaws .
+Added: Amendment No.
+Added: 1 to the Amended and Restated Bylaws.
Second Amended and Restated Bylaws .
Amendment No.
−Removed: 1 to the Second Amended and Restated Bylaws
−Removed: Supplement to Goldman Sachs & Co.
−Removed: LLC Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation
−Removed: Supplement to JPMorgan Chase Bank, National Association Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation
+Added: 1 to Second Amended and Restated Bylaws of Sarepta Therapeutics, Inc.
+Added: Credit Agreement, dated February 13, 2025, among Sarepta Therapeutics, Inc., Sarepta Therapeutics Investments, Inc., JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto
Certification of the Company’s Principal Executive Officer, Douglas S.
10 unchanged sentences
Indicates management contract or compensatory plan, contract or arrangement.
−Removed: * Certain identified information has been excluded from the exhibit.
+Added: * Identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
** The Certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filings of Sarepta Therapeutics, Inc.
2 unchanged sentences
SAREPTA THERAPEUTICS, INC.
−Removed: November 6, 2024
/s/ DOUGLAS S.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 6, 2024
Executive Vice President, Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.